Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.68 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | AR | P10275 | 1/20 | 0.63 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.63 |
| ▸ | XDH | P47989 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4254460 | 0.97 | PTGS1 (0.71) | PTGS1ALOX5ALDH1A1CYP3A4AR | |
| Eugenyl Acetate SCHEMBL5138181 | 0.90 | PTGS1 (0.82) | PTGS1ALOX5ALDH1A1CYP3A4AR | |
| Eugenol SCHEMBL27608718 | 0.87 | ALDH1A1 (0.85) | PTGS1ALOX5ALDH1A1CYP3A4AR | |
| Eugenol SCHEMBL29943804 | 0.87 | ALDH1A1 (0.85) | PTGS1ALOX5ALDH1A1CYP3A4AR | |
| Eugenol SCHEMBL114133 | 0.87 | ALDH1A1 (0.85) | PTGS1ALOX5ALDH1A1CYP3A4AR | |
| Eugenyl Acetate SCHEMBL26667569 | 0.86 | PTGS1 (0.87) | PTGS1ALOX5ALDH1A1CYP3A4AR | |
| Eugenol SCHEMBL27710638 | 0.85 | ALDH1A1 (0.82) | PTGS1ALOX5ALDH1A1CYP3A4AR | |
| SCHEMBL11891610 | 0.84 | PTGS1 (0.85) | PTGS1ALOX5ALDH1A1CYP3A4AR | |
| Aspirin SCHEMBL27980610 | 0.82 | PTGS1 (0.62) | PTGS1ALOX5ALDH1A1CYP3A4AR | |
| Hydroxychavicol SCHEMBL1657169 | 0.81 | XDH (0.79) | PTGS1ALOX5ALDH1A1CYP3A4AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387443-A1 | ENHANCING ONCOLYTIC VIROTHERAPY WITH A COMBINATION OF NUCLEAR EXPORT INHIBITOR AND MYXOMA VIRUS ACTIVATING CELL DEATH PATHWAYS | UNIV ARIZONA STATE (US) | 2025-12-25 | — | — | US | claimed |
| US-20250249056-A1 | CANCER THERAPIES COMPRISING A NUCLEAR EXPORT INHIBITOR AND AN ONCOLYTIC VIRUS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2025-08-07 | — | — | US | claimed |
| EP-4580612-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-07-09 | — | — | EP | claimed |
| US-20240277810-A1 | INTERFERONS AND NUCLEAR EXPORT INHIBITORS FOR USE IN METHODS OF TREATING CANCER | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2024-08-22 | — | — | US | claimed |
| WO-2024047248-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-03-07 | — | — | WO | claimed |
| CN-117320565-A | Composition containing 1' -acetoxychavicol acetate and acetoeugenol | 三得利控股株式会社 | 2023-12-29 | — | — | CN | claimed |
| WO-2023192955-A2 | CANCER THERAPIES COMPRISING A NUCLEAR EXPORT INHIBITOR AND AN ONCOLYTIC VIRUS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-10-05 | — | — | WO | claimed |
| EP-4100034-A1 | COMPOSITIONS COMPRISING EXTRACTS OF APLINIA AND OTHER PLANTS FOR IMPROVING JOINT HEALTH AND TREATING ARTHRITIS | Unigen, Inc. (US) | 2022-12-14 | — | — | EP | claimed |
| WO-2022256211-A1 | INTERFERONS AND NUCLEAR EXPORT INHIBITORS FOR USE IN METHODS OF TREATING CANCER | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2022-12-08 | — | — | WO | claimed |
| US-20220339166-A1 | POST COVID19 VACCINE REMEDIES | IPRX, LLC | 2022-10-27 | — | — | US | claimed |
| US-20170196836-A1 | Lung Cancer Adjuvant Therapy | TEXAS TECH UNIVERSITY SYSTEM | 2017-07-13 | — | — | US | claimed |
| CN-106046948-A | Inverter box | 江苏昌悦重工科技有限公司 | 2016-10-26 | — | — | CN | claimed |
| WO-2016089648-A1 | BACH 1 INHIBITORS IN COMBINATION WITH NRF2 ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS THEREOF | VTV THERAPEUTICS LLC (US) | 2016-06-09 | — | — | WO | claimed |
| CN-105287365-A | Compound podophyllotoxin gel for treating HPV virus and preparation method thereof | XU CHENG | 2016-02-03 | — | — | CN | claimed |
| WO-2015183983-A1 | LUNG CANCER ADJUVANT THERAPY | TEXAS TECH UNIVERSITY SYSTEM (US) | 2015-12-03 | — | — | WO | claimed |
| WO-2014195479-A1 | DRY PREPARATION OF ALPINIA GALANGA OR ALPINIA CONCHIGERA WITH HIGH CONTENT OF 1'S-1'-ACETOXYCHAVICOL ACETATE | NERTHUS APS (DK) | 2014-12-11 | — | — | WO | claimed |
| CN-103040802-A | Method for inhibiting reproduction of HIV-1 (human immunodeficiency virus-1) drug-resistant virus | YE YING | 2013-04-17 | — | — | CN | claimed |
| CN-102198096-B | ACA (acetoxychavicol acetate) submicron emulsion for intravenous injection, and preparation method and application thereof | HENAN MEDICAL SCIENCE RES INST | 2012-12-12 | — | — | CN | claimed |
| WO-2007088408-A1 | A METHOD OF CURING ANTIBIOTIC RESISTANT PLASMIDS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-08-09 | — | — | WO | claimed |
| CN-1309382-C | 1'-acetoxyl chavicol acetate with anti-HIV activity and its derivatives | HONGYI SCIENCE AND TECHNOLOGY (CN) | 2007-04-11 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277810-A1 | INTERFERONS AND NUCLEAR EXPORT INHIBITORS FOR USE IN METHODS OF TREATING CANCER | XPOT, XPO1, IFNAR1 | PTGS1 2803/4885ALOX5 3943/4885ALDH1A1 4697/4885 |
| US-20250387443-A1 | ENHANCING ONCOLYTIC VIROTHERAPY WITH A COMBINATION OF NUCLEAR EXPORT INHIBITOR AND MYXOMA VIRUS ACTIVATING CELL DEATH PATHWAYS | IL15RA, IL15, NXF1 | PTGS1 3442/4885ALOX5 2960/4885ALDH1A1 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.